NASDAQ:UMRX Cogent Biosciences (UMRX) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free UMRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$6.96▼$7.4050-Day Range$2.35▼$13.0152-Week Range$0.29▼$3.72Volume1.21 million shsAverage Volume1.22 million shsMarket Capitalization$295.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesSocial MediaStock AnalysisCompetitorsHeadlinesSocial Media Get Cogent Biosciences alerts: Email Address Ad Tips4TradersUncover this 2024 Hidden GemExclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.[Click here to subscribe] and elevate your trading today. About Cogent Biosciences Stock (NASDAQ:UMRX)Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.Read More Ad Tips4TradersUncover this 2024 Hidden GemExclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.[Click here to subscribe] and elevate your trading today. UMRX Stock News HeadlinesApril 24, 2024 | money.usnews.comCogent Biosciences IncFebruary 26, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT)April 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.February 26, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA)February 26, 2024 | markets.businessinsider.comCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsFebruary 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib with Strong Upside PotentialFebruary 14, 2024 | marketwatch.comCogent Biosciences Stock Soars After $225M Private PlacementFebruary 14, 2024 | msn.comCogent Biosciences announces oversubscribed $225M private placementApril 24, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...February 9, 2024 | markets.businessinsider.comBuy Rating on Cogent Biosciences Amid Market Overreaction and Promising Drug ProspectsFebruary 8, 2024 | msn.comCiti starts Cogent Biosciences at buy, cites GI tumor drug potentialDecember 15, 2023 | markets.businessinsider.comBuy Rating Reiterated for Cogent Biosciences as Bezuclastinib Shows Promise in SUMMIT TrialDecember 13, 2023 | markets.businessinsider.comMaintaining Buy on Cogent Biosciences Amid Anticipation of Differentiating Data for BezuclastinibDecember 11, 2023 | markets.businessinsider.comCogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis TreatmentDecember 11, 2023 | markets.businessinsider.comDow Surges 100 Points; Cogent Biosciences Shares PlungeDecember 11, 2023 | markets.businessinsider.comCogent Reports Positive Data From Phase 2 APEX Trial Of Bezuclastinib In Systemic MastocytosisDecember 11, 2023 | msn.comCogent slumps after mid-stage data for rare disorder therapyNovember 21, 2023 | markets.businessinsider.comPotential Upside for Cogent Biosciences Due to Imminent Data Readout for Bezuclastinib and Underpriced SharesNovember 14, 2023 | markets.businessinsider.comPromising Clinical Trials and Strong Financial Position Justify Buy Rating for Cogent BiosciencesNovember 4, 2023 | markets.businessinsider.comPromising Clinical Trials and Strong Financial Position Support Buy Rating for Cogent BiosciencesOctober 28, 2023 | markets.businessinsider.comPromising Market Potential for Cogent Biosciences’ Bezuclastinib Spurs Buy RatingAugust 30, 2023 | benzinga.comAnalyst Expectations for Cogent Biosciences's FutureAugust 15, 2023 | msn.comCogent Biosciences Is Beginning To Differentiate Its KIT InhibitorAugust 8, 2023 | markets.businessinsider.comLifeSci Capital Remains a Buy on Cogent Biosciences (COGT)July 11, 2023 | msn.comDoes Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect?June 13, 2023 | marketwatch.comCogent Biosciences Shares Rise on Fairmount Funds Management's Stake AcquisitionJune 12, 2023 | markets.businessinsider.com9 Analysts Have This to Say About Cogent BiosciencesSee More Headlines Receive UMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2020Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:UMRX CUSIPN/A CIK1622229 Webwww.unumrx.com Phone(617) 945-5576FaxN/AEmployees72Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,830,000.00 Net Margins-96.84% Pretax MarginN/A Return on Equity-87.78% Return on Assets-52.14% Debt Debt-to-Equity Ratio0.18 Current Ratio2.90 Quick Ratio2.90 Sales & Book Value Annual Sales$22.50 million Price / Sales13.14 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book6.69Miscellaneous Outstanding Shares42,469,000Free FloatN/AMarket Cap$295.58 million OptionableNot Optionable Beta3.93 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesAndrew R. RobbinsPresident, Chief Executive Officer & DirectorGeoffrey HodgeChief Technical Officer & Senior VP-OperationsJohn L. GreenChief Financial & Accounting OfficerJessica SachsChief Medical OfficerGreg MotzHead-ResearchKey CompetitorsKamadaNASDAQ:KMDANeoleukin TherapeuticsNASDAQ:NLTXCorMedixNASDAQ:CRMDErascaNASDAQ:ERASVerrica PharmaceuticalsNASDAQ:VRCAView All Competitors UMRX Stock Analysis - Frequently Asked Questions How were Cogent Biosciences' earnings last quarter? Cogent Biosciences, Inc. (NASDAQ:UMRX) announced its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.03. The company earned $0.53 million during the quarter. Cogent Biosciences had a negative net margin of 96.84% and a negative trailing twelve-month return on equity of 87.78%. What other stocks do shareholders of Cogent Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), KushCo (KSHB), Novan (NOVN), Aeterna Zentaris (AEZS) and Zosano Pharma (ZSAN). When did Cogent Biosciences IPO? Cogent Biosciences (UMRX) raised $75 million in an initial public offering (IPO) on Thursday, March 29th 2018. The company issued 5,800,000 shares at $12.00-$14.00 per share. Morgan Stanley and Cowen served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers. This page (NASDAQ:UMRX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingNew Trump BombshellThe Freeport SocietyThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
